March 10, 2020 / 10:10 AM / in 19 days

BRIEF-Mesoblast To Evaluate Anti-Inflammatory Cell Therapy Remestemcel-L For Covid-19

March 10 (Reuters) - Mesoblast Ltd:

* MESOBLAST TO EVALUATE ANTI-INFLAMMATORY CELL THERAPY REMESTEMCEL-L FOR TREATMENT OF COVID-19 LUNG DISEASE

* MESOBLAST LTD - REMESTEMCEL-L IS BEING STUDIED IN NUMEROUS CLINICAL TRIALS ACROSS SEVERAL INFLAMMATORY CONDITIONS

* MESOBLAST LTD - REMESTEMCEL-L HAS POTENTIAL FOR USE IN TREATMENT OF ARDS, WHICH IS PRINCIPAL CAUSE OF DEATH IN COVID-19 INFECTION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below